Uterine Atony Clinical Trial
Official title:
Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery
Verified date | November 2008 |
Source | IWK Health Centre |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
This study is designed to determine the minimum effective dose (ED90) of infusions of
oxytocin for the prevention of uterine atony / postpartum hemorrhage and the need for
additional uterotonics, in low risk parturients presenting for an elective CD.
The primary outcome measure is the response of effective uterine contraction as either
satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin
infusion dose. Secondary outcomes will include need for additional uterotonics, calculated
intra-operative blood loss and presence of oxytocin related adverse effects.
Status | Completed |
Enrollment | 40 |
Est. completion date | August 2008 |
Est. primary completion date | August 2008 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Non-emergent cesarean delivery with planned spinal anesthesia (i.e. elective planned cesarean delivery for malposition, patient choice, cervical pelvic disproportion, previous cesarean delivery and other diagnosis that require a predetermined cesarean delivery) 2. American Society of Anesthesia physical status class I & II (ASA I - Healthy, ASA II - mild and controlled systemic disease, eg. controlled essential hypertension) 3. Age = 18 years 4. Term gestational age (= 37 weeks) 5. English-speaking Exclusion Criteria: 1. Morbid Obesity (Body Mass Index = 45 kg/m2) (Morbidly obese parturients require a dose of local anesthetic less than the standardized dose in this study and the blood pressure cuff occasionally needs to be replaced by an intraarterial catheter due to limitations in size) 2. Laboring women 3. Urgent or emergency cesarean delivery 4. Severe hypertensive disease of pregnancy defined as systolic blood pressure (SBP) > 160mmHg, diastolic blood pressure (DBP) > 110mmHg and/or requiring antihypertensive treatment or associated with significant proteinuria 5. Severe maternal cardiac disease 6. Subjects predisposed to uterine atony and postpartum hemorrhage (i.e. placenta previa, multiple gestation, macrosomia, polyhydramnios, uterine abnormalities, or bleeding diathesis, > 2 previous CD) 7. Fetal anomalies /Intrauterine Fetal Demise 8. Failed spinal anesthesia 9. Patient enrollment in another study involving a study medication within 30 days of CD 10. Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Canada | IWK Health Centre | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
IWK Health Centre |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose. | 3 minutes | No | |
Secondary | Secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects. | 2 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02910115 -
Cooling the Uterus in C-section After Dysfunctional Labor
|
N/A | |
Withdrawn |
NCT02410655 -
An Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery
|
Phase 4 | |
Completed |
NCT00790062 -
Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT
|
Phase 4 | |
Recruiting |
NCT01579201 -
ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery
|
Phase 4 | |
Completed |
NCT03867383 -
Calcium Chloride for Prevention of Uterine Atony During Cesarean
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03584854 -
Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
|
Phase 4 | |
Completed |
NCT02780245 -
Role of Tranexamic Acid Versus Uterine Cooling at Caesarean Section
|
Phase 4 | |
Withdrawn |
NCT03303235 -
Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections
|
Early Phase 1 | |
Completed |
NCT02229513 -
Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT06192836 -
Placental Removal Method And Uterine Massage On Preventing Postpartum Hemorrhage
|
||
Recruiting |
NCT03413917 -
Exploration and Determination of Genomic Markers Predictive of Uterine Atony
|
||
Withdrawn |
NCT01252342 -
Does Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?
|
Phase 4 | |
Completed |
NCT04690153 -
Novel Approach of Hayman Uterine Compression Sutures for Management of Severe Atonic Postpartum Hemorrhage: Three Vertical Sutures
|
||
Completed |
NCT05027048 -
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
|
Phase 3 | |
Completed |
NCT01630187 -
Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony, During Elective Cesarean Section
|
Phase 4 | |
Completed |
NCT01549223 -
Oxytocin And Uterotonic Agent Use For Cesarean Delivery
|
Phase 4 |